Femasys Inc. (NASDAQ: FEMY) saw its shares climb roughly 30% in Friday's trading session, closing at $0.438, up from the previous close of $0.3373. The rally came on exceptionally heavy volume of nearly 15 million shares, far exceeding the stock's average daily turnover of about 536,350 shares. After-hours trading showed further volatility, with quotes reaching $0.5102.
Despite the sharp gain, Femasys stock remains below the $1 minimum bid price required by Nasdaq. The company has until July 13, 2026, to meet this requirement, needing to close at or above $1 for ten consecutive trading days. The rally did little to alleviate this listing concern.
The surge in volume suggests speculative interest rather than fundamental news, as no new company filings or announcements emerged in the past 48 hours. The broader market saw modest gains, with the Russell 2000 rising 0.9%, the Nasdaq Composite adding 0.2%, and the S&P 500 climbing 0.4%.
Femasys' most recent significant news came earlier this month. On May 13, the company announced CE Mark approval for its FemHSG catheter, allowing it to pursue commercial partnerships in Europe. The device meets European safety, health, and environmental standards for sale. That same day, the company filed an updated investor presentation.
In its first-quarter earnings report on May 8, CEO Kathy Lee-Sepsick highlighted progress across the company's platforms, including FemBloc and FemaSeed. The company reported Q1 sales of $424,889, a 24.5% increase from $341,264 in the prior-year period. Net income stood at $846,100, though this included gains from fair value changes in financial instruments. Net income attributable to common stockholders was $328,646.
Cash position remains a key concern. As of March 31, Femasys held $5.39 million in cash and cash equivalents, which management expects to fund operations through the third quarter of 2026. The company has flagged the need for additional financing in its 10-Q filing, warning that any new stock sale could dilute existing shareholders.
Shareholders have authorized a reverse stock split in the range of 1-for-2 to 1-for-25, giving the board flexibility to determine terms before May 1, 2027. While a reverse split could temporarily boost the share price above $1, it does not address underlying operational or cash flow challenges.
Femasys operates in the women's health space, focusing on in-office gynecology devices. It faces competition from larger players like Progyny, which targets employer fertility benefits, and CooperSurgical, which offers reproductive-care products. Femasys remains a smaller player with a narrower product lineup.
U.S. markets are closed Monday for Memorial Day, with trading resuming Tuesday, May 26. Femasys heads into the long weekend with some price momentum, but the core issue remains: converting product approvals and trial progress into sustainable revenue before its cash runway runs out.
